ReviewBiomarkers in cancer2015
Interleukin 1β-A Potential Salivary Biomarker for Cancer Progression?
Review in Biomarkers in cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Harnessing pyroptosis in breast cancer therapy: immunological mechanisms and emerging biomaterial strategies.Cell death discovery · 2026Review
- Modelling the ageing dependence of cancer evolutionary trajectories.Nature reviews. Cancer · 2025Review
- Evaluation of the Association between Genetic Polymorphism of Interleukin-1 Beta (-511C/T and +3953C/T) and Cervical Cancer Susceptibility.South Asian journal of cancer · 2025Article
- Natural and induced immune responses in oral cavity and saliva.BMC immunology · 2025Review
- Prokaryotic organelle mitochondria drive tumorigenesis: "the original sin".Frontiers in oncology · 2025Review
- Saliva in Balancing Oral and Systemic Health, Oral Cancer, and Beyond: A Narrative Review.Cancers · 2024Review
- Salivary Profile Analysis Based on Oral Cancer Risk Habits: An Observational Cross-Sectional Study.Biomedicines · 2024Article
- RETRACTED: Potential Antitumor Activity of Combined Lycopene and Sorafenib against Solid Ehrlich Carcinoma via Targeting Autophagy and Apoptosis and Suppressing Proliferation.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Plasmon resonance biosensor for interleukin-1β point-of-care determination: A tool for early periodontitis diagnosis.iScience · 2024Article
- Serum and Bronchoalveolar Lavage Fluid Levels of Cytokines in Patients with Lung Cancer and Chronic Lung Disease: A Prospective Comparative Study.Journal of personalized medicine · 2023Article
- Interleukins (Cytokines) as Biomarkers in Colorectal Cancer: Progression, Detection, and Monitoring.Journal of clinical medicine · 2023Review
- Detection of IL-1β, VEGF and IL-4 with their novel genetic variations in breast cancer patients.Saudi journal of biological sciences · 2023Article
- (-)-Epigallocatechin-3-Gallate Prevents IL-1β-Induced uPAR Expression and Invasiveness via the Suppression of NF-κB and AP-1 in Human Bladder Cancer Cells.International journal of molecular sciences · 2022Article
- The impact of tobacco smoking and electronic cigarette vaping on salivary biomarkers. A comparative study.The Saudi dental journal · 2022Article
- Low social and family well-being is associated with greater RAGE ligand s100A8/A9 and interleukin-1 beta levels in metastatic breast cancer patients.Brain, behavior, & immunity - health · 2022Article
- Synaptic effects of IL-1β and CRF in the central amygdala after protracted alcohol abstinence in male rhesus macaques.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Article
- Using Salivary Biomarkers for Stress Assessment in Offshore Saturation Diving: A Pilot Study.Frontiers in physiology · 2021Article
- The Role of Interleukin 1β in the Pathogenesis of Lung Cancer.JTO clinical and research reports · 2020Review
- The Correlation betweenJournal of breast cancer · 2019Article
- Hypothesis: Induction of biomarkers for detection of colonic neoplasms.Journal of Cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between cancer and inflammation is a complex but intimate one. Decades of work has shown to us that cancer progression is influenced by a multitude of factors, including genetic, environmental, and immunological factors. We often overlook that cancer progression is also a pathological consequence of a dysregulated inflammatory control in the body. A current emerging topic in cancer research is the role of inflammasomes in carcinogenesis. The inflammasome is a multicomplex protein platform that when activated results in the release of proinflammatory cytokines, such as interleukin (IL)-1β. There is increasing evidence suggesting that IL-1β plays a pivotal role in cancer progression. This short review proposes the possibility of using IL-1β as a potential cancer progression biomarker and discusses the use of saliva as a model biological fluid for measuring physiological IL-1β levels in the body.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.